Skip to Main Content

Author Details

Kyung Park
New York University Langone Health
2010
31
22
PMIDPaper TitleJournal TitlePublished Year
37307880Correlation of Programmed Death-Ligand 1 Expression With Lung Adenocarcinoma Histologic and Molecular Subgroups in Primary and Metastatic Sites.Mod Pathol2023
37307880Correlation of Programmed Death-Ligand 1 Expression With Lung Adenocarcinoma Histologic and Molecular Subgroups in Primary and Metastatic Sites.Mod Pathol2023
35050902Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.JCI Insight2022
35526304Malignant lymphoma of the lower urinary tract: A single institutional experience.Pathol Res Pract2022
35050902Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.JCI Insight2022
35526304Malignant lymphoma of the lower urinary tract: A single institutional experience.Pathol Res Pract2022
32598087Next-generation sequencing of residual cytologic fixative preserved DNA from pancreatic lesions: A pilot study.Cancer Cytopathol2020
32045275Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.Arch Pathol Lab Med2020
32598087Next-generation sequencing of residual cytologic fixative preserved DNA from pancreatic lesions: A pilot study.Cancer Cytopathol2020
32045275Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.Arch Pathol Lab Med2020
29202479SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.J Clin Invest2018
29202479SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.J Clin Invest2018
28762374Molecular alterations in prostate cancer and association with MRI features.Prostate Cancer Prostatic Dis2017
28762374Molecular alterations in prostate cancer and association with MRI features.Prostate Cancer Prostatic Dis2017
29333526Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.JCO Precis Oncol2017
29333526Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.JCO Precis Oncol2017
26181256Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.JAMA Oncol2015
26181256Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.JAMA Oncol2015
24297949TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.J Clin Oncol2014
25415230The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.Nat Commun2014
24297949TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.J Clin Oncol2014
25128228Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.Hum Pathol2014
24563616SPOP mutations in prostate cancer across demographically diverse patient cohorts.Neoplasia2014
25056375Evidence for molecular differences in prostate cancer between African American and Caucasian men.Clin Cancer Res2014
25415230The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.Nat Commun2014
25056375Evidence for molecular differences in prostate cancer between African American and Caucasian men.Clin Cancer Res2014
25128228Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.Hum Pathol2014
24563616SPOP mutations in prostate cancer across demographically diverse patient cohorts.Neoplasia2014
22981675Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.Eur Urol2013
22944196Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.Urol Oncol2013
22981675Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.Eur Urol2013
23856515V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application.Hum Pathol2013
23358695Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.Neoplasia2013
23233736Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.Cancer Res2013
23348902Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.Mod Pathol2013
23555183Epigenomic alterations in localized and advanced prostate cancer.Neoplasia2013
23622249Punctuated evolution of prostate cancer genomes.Cell2013
23381693Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.Prostate Cancer Prostatic Dis2013
23856515V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application.Hum Pathol2013
23622249Punctuated evolution of prostate cancer genomes.Cell2013
23381693Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.Prostate Cancer Prostatic Dis2013
23555183Epigenomic alterations in localized and advanced prostate cancer.Neoplasia2013
23233736Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.Cancer Res2013
23358695Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.Neoplasia2013
23348902Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.Mod Pathol2013
22944196Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.Urol Oncol2013
22610119Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.Nat Genet2012
22610119Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.Nat Genet2012
22555088Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.Diagn Mol Pathol2012
23169519Challenges in recognizing treatment-related neuroendocrine prostate cancer.J Clin Oncol2012
  • 1 - 50 of 62

Recommended Authors

Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 39
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 10
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2014
Number of shared co-authors 16
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 1
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 2012
Number of shared co-authors 0
University of British Columbia
Career Start Year 2011
Number of shared co-authors 8
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2011
Number of shared co-authors 30
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 11
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 25
The Institute of Cancer Research
Career Start Year 2008
Number of shared co-authors 30
University of British Columbia
Career Start Year 2007
Number of shared co-authors 17
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 28
Centre hospitalier de l'Universite de Montreal
Career Start Year 2006
Number of shared co-authors 0
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 2006
Number of shared co-authors 0
Johns Hopkins University School of Medicine
Career Start Year 2006
Number of shared co-authors 30
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 18
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 6
Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 0
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 10
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 4
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Career Start Year 2000
Number of shared co-authors 35
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 18
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 36
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 17
University College London
Career Start Year 1999
Number of shared co-authors 0
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1997
Number of shared co-authors 0
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 18
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 31
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 4
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 11

Collaborators

University of Bern
Co-authored papers 28
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 22
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 15
University of Trento
Co-authored papers 11
Institute for Computational Biomedicine
Co-authored papers 11
Dana-Farber Cancer Institute
Co-authored papers 11
Co-authored papers 10
Weill Cornell Medical College
Co-authored papers 9
Sandra and Edward Meyer Cancer Center
Co-authored papers 9
Meyer Cancer Center
Co-authored papers 8
Sandra and Edward Meyer Cancer Center
Co-authored papers 6
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 6
Co-authored papers 5
Institut Curie, CNRS, PSL Research University
Co-authored papers 5
University of Michigan Medical School.
Co-authored papers 5
University of California
Co-authored papers 4
Weill Cornell Medicine and New York Presbyterian Hospital
Co-authored papers 4
Meyer Cancer Center
Co-authored papers 4
Broad Institute of Harvard and MIT
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Yale University
Co-authored papers 3
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 3
Broad Institute of MIT and Harvard
Co-authored papers 3
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 3
Co-authored papers 3
The Broad Institute of Harvard and MIT
Co-authored papers 3
Co-authored papers 3
University of Trento
Co-authored papers 3
Broad Institute
Co-authored papers 3